PRO 140, PRO 542, PRO 2000

PRO 140 is a humanized monoclonal antibody designed to block the ability of HIV to infect cells by inhibiting virus-cell binding.

Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study - 9/28/07

Tolerability and Antiviral Efficacy of CCR5 Monoclonal Antibody PRO 140 - 8/10/07

Progenics Announces Results from First Clinical Trial of CCR5 Inhibitor PRO 140 - 5/04/07

Experimental Entry Inhibitor PRO 140 Wins "Fast Track" Designation from FDA - 2/28/06

PRO 542 is an experimental entry inhibitor being developed by Progenics Pharmaceuticals. PRO 542 is a protein that has been designed to inhibit HIV entry by binding onto the gp120 region of HIV (one of the proteins sticking out from the surface of the virus used to engage with CD4 receptors on the surface of lymphocytes).

Experimental Entry Inhibitor PRO 542 Shows Early Promise as Salvage Therapy for Advanced HIV Disease - 3/22/04

PRO 2000 is an experimental anti-HIV drug being developed by Procept Inc. It is designed to work by targeting the CD4 molecule, preventing HIV's gp120 molecule from binding onto cells and infecting them.

FDA-Approved Treatments
for HIV/AIDS

Experimental Treatments
for HIV/AIDS